Stefan Schulz Selected Research

CXCR4 Receptors (CXCR4 Receptor)

7/2022	Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.
9/2020	Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.
10/2019	Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
4/2010	Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer?
1/2008	Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Schulz Research Topics

Disease

43	Neoplasms (Cancer) 11/2021 - 11/2003
14	Pain (Aches) 01/2022 - 12/2006
11	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2016 - 11/2008
7	Inflammation (Inflammations) 01/2022 - 12/2006
5	Pituitary Neoplasms (Pituitary Adenoma) 06/2021 - 10/2006
5	Adenoma (Adenomas) 11/2013 - 04/2008
4	Respiratory Insufficiency (Respiratory Failure) 01/2022 - 01/2018
4	Opioid-Related Disorders (Opiate Addiction) 01/2021 - 05/2004
4	Carcinoma (Carcinomatosis) 09/2015 - 09/2006
4	Carcinoid Tumor (Carcinoid) 03/2015 - 02/2009
3	Constipation 01/2020 - 01/2018
3	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2009
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2018 - 11/2011
3	Dehydration (Water Stress) 01/2017 - 11/2002
3	Arthritis (Polyarthritis) 07/2014 - 06/2011
3	Hyperalgesia 07/2014 - 06/2011
3	Growth Hormone-Secreting Pituitary Adenoma 11/2013 - 04/2008
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2021
2	Chronic Pain 01/2020 - 01/2018
2	Adenocarcinoma 10/2019 - 10/2018
2	Lymphoma (Lymphomas) 01/2017 - 11/2016
2	Astrocytoma (Pilocytic Astrocytoma) 08/2013 - 01/2004
2	Bites and Stings (Sting) 09/2010 - 01/2004
2	Pituitary ACTH Hypersecretion 02/2010 - 02/2009
2	Acromegaly 02/2010 - 02/2009
2	Brain Ischemia (Cerebral Ischemia) 07/2008 - 07/2002
2	Pheochromocytoma 06/2008 - 11/2003
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2006 - 09/2006
2	Glioblastoma (Glioblastoma Multiforme) 09/2006 - 01/2004
2	Ischemia 12/2004 - 07/2002
1	Thyroid Neoplasms (Thyroid Cancer) 07/2022
1	Follicular Adenocarcinoma 07/2022
1	Anaplastic Thyroid Carcinoma 07/2022
1	Malaria 01/2021
1	Hemolysis 01/2021
1	Glaucoma 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Sepsis (Septicemia) 01/2021
1	Neuroendocrine Carcinoma 09/2020
1	Prostatic Neoplasms (Prostate Cancer) 09/2020
1	Delirium 01/2020
1	Infections 01/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2018
1	Brain Neoplasms (Brain Tumor) 07/2018
1	Pruritus (Itching) 01/2018

Drug/Important Bio-Agent (IBA)

31	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 07/2022 - 11/2003
26	Somatostatin Receptors (Somatostatin Receptor)IBA 07/2022 - 03/2002
15	Chemokine ReceptorsIBA 07/2022 - 07/2002
13	Monoclonal AntibodiesIBA 07/2022 - 01/2008
11	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2005
11	Proteins (Proteins, Gene)FDA Link 04/2015 - 11/2002
9	somatostatin receptor 2IBA 11/2016 - 12/2004
8	Octreotide (Sandostatin)FDA LinkGeneric 06/2021 - 11/2003
8	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 12/2006
7	LigandsIBA 01/2022 - 12/2004
7	ParaffinIBA 10/2017 - 09/2006
7	AntibodiesIBA 11/2016 - 11/2003
7	Formaldehyde (Formol)FDA Link 03/2015 - 09/2006
6	GTP-Binding Proteins (G-Protein)IBA 01/2022 - 08/2012
6	Messenger RNA (mRNA)IBA 03/2015 - 09/2005
5	CXCR4 Receptors (CXCR4 Receptor)IBA 07/2022 - 01/2008
5	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 09/2011
5	ChemokinesIBA 10/2019 - 12/2006
5	somatostatin receptor type 1IBA 12/2017 - 08/2011
4	pasireotideIBA 06/2021 - 02/2009
4	Peptides (Polypeptides)IBA 10/2006 - 12/2004
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 10/2006
3	Analgesics (Analgesic Drugs)IBA 01/2020 - 03/2015
3	AntigensIBA 07/2014 - 06/2011
2	Pharmaceutical PreparationsIBA 06/2021 - 06/2011
2	Opioid Peptides (Opioid Peptide)IBA 01/2021 - 12/2006
2	Endothelin A ReceptorIBA 07/2018 - 10/2017
2	Endothelins (Endothelin)IBA 07/2018 - 06/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 08/2011 - 06/2011
2	Chemokine CXCL12IBA 01/2011 - 07/2002
2	Biological ProductsIBA 01/2011 - 12/2005
2	Membrane Proteins (Integral Membrane Proteins)IBA 06/2010 - 11/2002
2	Protein Isoforms (Isoforms)IBA 07/2009 - 07/2002
1	6'- fluoro- 4',9'- dihydro- N,N- dimethyl- 4- phenylspiro(cyclohexane- 1,1'(3'H)- pyrano(3,4- b)indol)- 4- amineIBA 01/2022
1	ArrestinIBA 07/2021
1	NociceptinIBA 01/2021
1	CannabinoidsIBA 01/2021
1	Odorant Receptors (Odorant Receptor)IBA 01/2021
1	Acyl-ButyrolactonesIBA 01/2021
1	Complement C5a (Complement 5a)IBA 01/2021
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2021
1	Volatile Organic CompoundsIBA 01/2021
1	Anaphylatoxin C5a ReceptorIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2020
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2020
1	Fentanyl (Sublimaze)FDA LinkGeneric 01/2020
1	AlkaloidsIBA 01/2019
1	TRK 820IBA 01/2018
1	MorphinansIBA 01/2018

Therapy/Procedure

10	Therapeutics 07/2022 - 12/2005
6	Analgesia 07/2021 - 12/2006
2	Radiotherapy 01/2012 - 10/2006
1	Length of Stay 01/2020